Lates News

According to AI Express, Open Source Securities released a research report on April 28, giving Xin Qi Eyedrops (300573.SZ) a "buy" rating. The reasons for the rating mainly include: 1) Building a series of ophthalmic drug varieties, steadily advancing the new drug pipeline; 2) Rapid growth in performance, with the low-concentration atropine expected to continue to increase in volume by 2026, maintaining a "buy" rating. (Daily Economic News)